17 min. Read

The Pear Therapeutics Report

In this article:

In this 4,500-word report, E&O digs into the strategic moves, challenges, and successes that the Pear Therapeutics executive team has navigated since its founding five years ago. The report covers dozens of Pear’s therapeutic areas of interest; financial details from licensing agreements the company has forged with academic researchers; why it acquired a small tech startup in its early years; its failed direct-to-consumer products and more.

Fresh from vacation, ex-McKinsey analyst and then-venture capitalist Corey McCann M.D. Ph.D. stepped up to the mic at the first-ever NeuroGaming conference in 2013 and asked a question. Well, three

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
The Spring Health Report
20 min. Read
The Sword Health Report
21 min. Read
The Big Health Report
29 min. Read
The Virta Health Report
31 min. Read
Who controls the Spice?
25 min. Read
The Noom Report
39 min. Read
The Crossover Health Report
22 min. Read
Analysis: Livongo founders’ HAAC SPAC
11 min. Read
The UnitedHealth Group Report
30 min. Read
The Virgin Pulse Report
14 min. Read
  • First
  • Previous
  • 1 of 2
  • Next
  • Last